SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Zepbound " 20 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
FSU HEALTH COMMUNICATION EXPERT FINDS GLP-1 USERS FACE STIGMA WITHIN THEIR SOCIAL CIRCLES
Sept 24 2026 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a Florida State University professor. Braidyn Lazenby, an assistant professor at FSU’s College of Communication & Information, led the study “‘They Call Us Cheaters:” Exploring Stigma […]
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks
Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the preparation, the U.S. drugmaker said in a public letter released on Thursday.
CVS blows past estimates, hikes guidance as insurance unit continues to improve
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
Weight loss medications heavy on Fort Worth’s employee health plan
Skyrocketing use of weight loss medications such as Ozempic, Wegovy and Zepbound drives up insurance claims for the city of Fort Worth.
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.
BBC Audio | Business Daily | The worldwide weight-loss revolution
Drugs like Ozempic, Wegovy, Mounjaro and Zepbound are reshaping global obesity treatment
Experimental compound helps burn fat without muscle loss
A decades-old compound may point to a new way of treating obesity by making the body burn more energy rather than simply reducing appetite. In mice, TOFA increased energy use by as much as 18%, reduced body fat without significant muscle loss, and improved blood sugar, triglycerides, and fatty liver disease. It also produced stronger results when combined with GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.
Popular Weight Loss Drugs May Have Surprising Side Effect: Stalling Cancer
A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.
Demand for GLP-1 pills and shots surges, and not just for weight loss
Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they currently take the medications.
Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat
Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the finding could help explain the drug’s powerful benefits and inspire more comprehensive treatments for obesity and diabetes.
GLP-1 drug popularity is outpacing the science, Madison doctor says
Dr. David Harris at UW-Madison says weight loss drugs like Ozempic, Wegovy and Zepbound are safe, so long as patients get the medications from doctors.
Restrictions on obesity drug coverage force patients to pivot
Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.
Wegovy and Zepbound are changing how Americans get health care
Ozempic, Wegovy and Zepbound have helped Americans lose weight, cut demand for weight-loss operations and improved heart health.
FSU Health Communication expert finds GLP-1 users face stigma within their social circles
People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a
Forbes Daily: Gen Z Leaders Now Dominate The Forbes 30 Under 30
Today’s Forbes Daily newsletter covers the new 30 Under 30 list, Sam Altman’s OpenAI memo, NYC casino proposals move forward, Eli Lilly slashes Zepbound costs and more.
People taking GLP-1 weight loss drugs like Ozempic started moving less
People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long-term health.
GLP-1s 101: What the science says about weight loss, side effects, safety
We asked Stanford Medicine experts to break down everything you need to know about the drugs known as GLP-1s, semaglutide, Ozempic, Wegovy, Zepbound and many more.
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.